Expression and clinical significance of glucose transporters 1, monocarboxylate transporter 1 and monocarboxylate transporter 4 in colon cancer

Abstract

Objective To investigate the correlation between the expression of glucose transporters 1 (GLUT1), monocarboxylate transporter 1 (MCT1), monocarboxylate transporter 4(MCT4) and clinical characteristics in colon cancer. Methods From January 2008 to January 2016, the carcinoma tissues of 84 cases with colon cancer after gastrointestinal surgery, and 40 samples of corresponding adjacent normal colon tissues in the First People's Hospital of Hangzhou were collected.The clinical data were collected.Immunohistochemistry was performed to detect the expression of GLUT1, MCT1 and MCT4, the results were analyzed. Results The positive expression rates of MCT1, GLUT1 and MCT4 in colon cancer were 54.8%(46/84), 47.6%(40/84), 58.3%(49/84), respectively, which were significantly higher than those of the control group[12.5%(5/40), 7.5%(3/40), 15.0%(6/40)], the differences were statistically significant (χ2=19.987, 19.253, 20.615, all P<0.01). The expressions of GLUT1, MCT1, and MCT4 were not related to gender, age and tumor size, but related to lesion location, differentiation, lymph node metastasis, distant metastasis and clinical stage(GLUT1: χ2=6.227, 11.629, 10.029, 14.817, 4.709; MCT1: χ2=6.891, 8.615, 9.185, 5.337, 16.131; MCT4: χ2=8.641, 7.077, 12.131, 6.917, 7.077; all P<0.05). Conclusion High expression of GLUT1, MCT1 and MCT4 were observed in colon cancer.GLUT1, MCT1 and MCT4 may affect the development of colon cancer through energy metabolism pathway in colon cancer tissues. Key words: Glucose transport proteins, facilitative; Monocarboxylate transporter 1; Monocarboxylate transporter 4; Colonic neoplasms; Energy metabolism; Neoplasm metastasis; Immunohistochemistry; Pathology, clinical